EN DE
Watch ORUM for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ORUM (475830) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of ORUM stock KRW 6,548, price KRW 15,000, that is 56.3% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7475830006

O ORUM logo Thin data Nov 10, 2026

ORUM

475830 · KQ

Far too expensive (fair value 56% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Ranks above peers (5/8) 
Fair value 6,548 KRW · Strongly overvalued 
Quality 29/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −32.3 %/yr in KRW) 
Negative free cash flow 
Narrow moat 28/100 · thin data
Thin data 
Estimate
Watch ORUM for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

143,700 KRW 14,420 KRW Fair Value 6,548 KRW Feb 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

21‑month range 14,420 KRW – 143,700 KRW · fair‑value band 4,911 KRW – 8,185 KRW · the 15,000 KRW price screens above the 6,548 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ORUM in your weekly email

Every Wednesday you see whether ORUM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States.

Show moreShow less

The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor.

It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.

Stock analysis

ORUM (475830) currently trades at 15,000 KRW, while our estimate is 6,548 KRW, 56% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 4,911 KRW (bear) to 8,185 KRW (bull), the price of 15,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ORUM reported revenue of 23.6M KRW in FY2025 versus 75.9M KRW in FY2022, a compound −32.3%/yr. Reported net income was −42.0B KRW in FY2025.

Key figures

Market cap 326B KRW (≈ $244M) Micro · P/E ratio 17.3 · EPS (TTM) 852.28 KRW · Return on equity 10.8% · Return on assets (EBIT) −45.5% (4-year average) · Operating margin −63,691% · Revenue (TTM) 40.6M KRW · Revenue growth (YoY) +479%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and 4% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −56%, 475830 screens richer than that median.

Fair Value

Bear 4,911 KRW Fair Value 6,548 KRW Bull 8,185 KRW
Price 15,000 KRW · Downside -56.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.3%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

475830 screens overvalued: fair value 56% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ORUM with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −56.3% · Bottom 25%
Profitability
Return on equity (12 months) 10.8% · Top 25%
Return on assets −24.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 479.1% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 17.3× · Cheaper than median
P/B 2.49× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)43 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 475830
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs 475830
Samsung Biologics Co 207940 1,411,000 KRW 1,573,000 KRW +11% vs 475830
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 475830
argenx SE ARGX $960.04 $908.40 −5% vs 475830
CSL Limited CSL A$202.92 A$183.54 −10% vs 475830
Moderna, Inc MRNA $223.37 $139.99 −37% vs 475830
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs 475830
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 475830
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 475830

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ORUM: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ORUM Fair Value". https://www.fairvalue-calculator.com/stock/475830

Frequently asked questions

Is ORUM (475830) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 6,548 KRW versus a price of 15,000 KRW, about 56% lower (overvalued).
What is the fair value of 475830?
Our estimate for ORUM is 6,548 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 15,000 KRW.
What is the quality score of 475830?
ORUM has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ORUM (475830)?
Our calculated price target is the estimate of 6,548 KRW (as of Nov 10, 2026). Cautious scenario 4,911 KRW, optimistic scenario 8,185 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ORUM stock forecast for 2026?
Our estimate puts fair value at 6,548 KRW, about 56% lower versus a price of 15,000 KRW (overvalued). Cautious scenario 4,911 KRW, optimistic scenario 8,185 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ORUM (475830)?
ORUM reported trailing-twelve-month revenue of about 40.6M KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of ORUM (475830)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ORUM it is 6,548 KRW per share (as of Nov 10, 2026), against a price of 15,000 KRW.
Is ORUM stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 475830 trades above its calculated fair value: price 15,000 KRW, fair value 6,548 KRW, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 475830?
No. The price is what the market pays today (15,000 KRW); the fair value is what the company's own numbers justify (6,548 KRW). For ORUM the two are 8,452 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ORUM worth?
The market values ORUM at about 326B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 15,000 KRW; our models calculate a fair value of 6,548 KRW per share.
What do the bullish and bearish scenarios say about 475830?
Our models span a range for ORUM: cautious scenario 4,911 KRW, base 6,548 KRW, optimistic 8,185 KRW per share (as of Nov 10, 2026, price 15,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 475830?
ORUM trades at a price-to-earnings ratio of 17.3 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6,548 KRW is built from several models across several years. Other multiples: P/B 2.5.
How solid is the balance sheet of ORUM (475830)?
Balance-sheet figures for ORUM (as of Nov 10, 2026): return on equity 10.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 475830 from its 52-week high?
ORUM trades at 15,000 KRW, about 90% below its 52-week high of 143,700 KRW and 4% above the low of 14,420 KRW (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of 6,548 KRW is for.
Which stocks are comparable to ORUM?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ORUM stock attractive at the current price?
The data as of Nov 10, 2026: price 15,000 KRW, calculated fair value 6,548 KRW (−56%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. ORUM itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ORUM (475830)?
The closing price on Nov 13, 2026 was 15,000 KRW. Our estimate is 6,548 KRW, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ORUM right now?
The price sits above even our optimistic bull case (8,185 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ORUM

How large is the market capitalisation of ORUM (475830)?
The market capitalisation of ORUM is 326B KRW (≈ $244M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ORUM (475830)?
Earnings per share at ORUM are 852.28 KRW (price ÷ EPS = P/E 17.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ORUM (475830)?
The return on equity (ROE) of ORUM is 10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ORUM (475830)?
On an EBIT basis the return on assets of ORUM is −45.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ORUM (475830)?
The operating margin of ORUM is −63,691% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ORUM (475830)?
Revenue at ORUM is growing +479% versus a year earlier (3y avg −32.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ORUM (475830) generate?
The free cash flow of ORUM is −36.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ORUM in the live analysis

One click puts ORUM on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.